Walter H. Moos - 20 Feb 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
Director
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
20 Feb 2026
Net transactions value
-$49,440
Form type
4
Filing time
24 Feb 2026, 16:58:28 UTC
Previous filing
28 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MOOS WALTER H Director RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO /s/ Raymond Furey (Attorney-in-Fact) 24 Feb 2026 0001190272

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Options Exercise $96,000 +4,000 +31% $24.00 16,722 20 Feb 2026 Direct F1
transaction RIGL Common Stock Sale $145,440 -4,000 -24% $36.36 12,722 20 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Stock Option (right to buy) Options Exercise $0 -4,000 -100% $0.000000 0 20 Feb 2026 Common Stock 4,000 $24.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F2 The shares vested monthly over twelve (12) months from the grant date of May 11, 2016.